Alpine Immune Sciences Inc (NASDAQ: ALPN) May Be Attracting Institutional Investments

After Hours

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Recently, Yahoo Finance discussed the stock, revealing that Alpine Immune Sciences to Present Updated Clinical Data for Povetacicept in IgA Nephropathy at the World Congress of Nephrology 2024.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

Stocks Info

Alpine Immune Sciences Inc is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. The current market capitalization of Alpine Immune Sciences Inc is $2.64B. A total of 1.2 million shares were traded on the day, compared to an average of 1.13M shares.

In the most recent transaction, Rickey James Paul sold 117,764 shares of ALPN for 23.32 per share on Jan 26 ’24. After the transaction, the insider now owns 0 company shares. In a previous transaction on Jan 25 ’24, Rickey James Paul sold 236 shares at 22.00 per share. ALPN shares that the insider owns now total 0.

Among the insiders who sold shares, ORBIMED ADVISORS LLC disposed of 1,364,849 shares on Dec 28 ’23 at a per-share price of $18.35. This resulted in the Director holding 264,315 shares of ALPN after the transaction. In another insider transaction, Thompson Peter A. sold 1,364,849 shares at $18.35 per share on Dec 28 ’23. Company shares held by the Director now total 264,315.

Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. In terms of 52-week highs and lows, ALPN has a high of $42.88 and a low of $6.71.

As of this writing, ALPN has an earnings estimate of -$0.42 per share for the current quarter. EPS was calculated based on a consensus of 7 estimates, with a high estimate of -$0.29 per share and a lower estimate of -$0.51. The company reported an EPS of -$0.24 in the last quarter, which was 27.30% higher than expectations of -$0.33.

Balance Sheet Annually/Quarterly

A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. ALPN’s latest balance sheet shows that the firm has $162.30M in Cash & Short Term Investments as of fiscal 2021. There were $19.63M in debt and $69.78M in liabilities at the time. Its Book Value Per Share was $5.43, while its Total Shareholder’s Equity was $120.90M.

Analysts Opinion

It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ALPN is Buy with a score of 4.88.

Most Popular

Related Posts